RAPP Key Statistics, Chart & Performance
The current stock price of RAPP is 27.66 USD. In the past month the price decreased by -6.24%. In the past year, price increased by 86.77%.
RAPP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.39 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.73 | 493.40B | ||
| MRK | MERCK & CO. INC. | 12.36 | 270.22B | ||
| PFE | PFIZER INC | 7.95 | 144.59B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.3 | 110.79B | ||
| ZTS | ZOETIS INC | 20.4 | 57.00B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.89 | 23.46B | ||
| VTRS | VIATRIS INC | 5.32 | 14.28B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.79 | 11.83B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.59B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.36B |
Related stock screener links
About RAPP
Company Profile
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. The company is headquartered in Boston, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2024-06-07. The company has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The company is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Company Info
RAPPORT THERAPEUTICS INC
99 High Street, Suite 2100
Boston MASSACHUSETTS US
Employees: 69
Phone: 18573218020
RAPPORT THERAPEUTICS INC / RAPP FAQ
What does RAPP do?
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. The company is headquartered in Boston, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2024-06-07. The company has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The company is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
What is the current price of RAPP stock?
The current stock price of RAPP is 27.66 USD. The price increased by 0.51% in the last trading session.
Does RAPP stock pay dividends?
RAPP does not pay a dividend.
What is the ChartMill rating of RAPPORT THERAPEUTICS INC stock?
RAPP has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for RAPP stock?
15 analysts have analysed RAPP and the average price target is 53.3 USD. This implies a price increase of 92.68% is expected in the next year compared to the current price of 27.66.
What is RAPPORT THERAPEUTICS INC worth?
RAPPORT THERAPEUTICS INC (RAPP) has a market capitalization of 1.32B USD. This makes RAPP a Small Cap stock.
RAPP Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RAPP. When comparing the yearly performance of all stocks, RAPP is one of the better performing stocks in the market, outperforming 92.01% of all stocks.
RAPP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RAPP. While RAPP has a great health rating, there are worries on its profitability.
RAPP Financial Highlights
Over the last trailing twelve months RAPP reported a non-GAAP Earnings per Share(EPS) of -2.71. The EPS decreased by -3.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.25% | ||
| ROE | -19.1% | ||
| Debt/Equity | 0 |
RAPP Forecast & Estimates
15 analysts have analysed RAPP and the average price target is 53.3 USD. This implies a price increase of 92.68% is expected in the next year compared to the current price of 27.66.